Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
2seventy bio (TSVT)
NASDAQ:TSVT
Holding TSVT?
Track your performance easily
Earnings Data
Report Date
Mar 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.17Last Year’s EPS
-1.11Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 22, 2022
|% Change Since: -48.04%
|Next Earnings Date:Dec 01, 2021
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in ABECMA revenues and significant cost reductions, indicating positive progress towards breakeven. Despite seasonal challenges and market competition, the company remains optimistic about future growth and operational efficiency.Company Guidance
During the Q3 2024 earnings call for 2seventy bio, significant guidance was provided regarding the company's focus and financial outlook. The executives highlighted a strategic shift towards prioritizing ABECMA, with U.S. revenues reaching $77 million in the third quarter, reflecting a 42% growth over the previous quarter. They projected total U.S. ABECMA revenues for 2024 to be in the range of $240 million to $250 million, noting a likely reduction in the fourth quarter due to seasonal factors. The company's burn rate was reduced to approximately $10 million this quarter, with operating expenses seeing a 24% reduction compared to the prior quarter. They also reported collaborative arrangement revenue of approximately $11 million with BMS. The company aims to achieve breakeven operations potentially by 2025, revising the breakeven sales point to closer to $300 million, down from $400 million initially projected. Looking ahead, the focus will be on competing commercially for ABECMA and optimizing cost structures to enhance operating margins.Significant Revenue Growth for ABECMA
ABECMA U.S. revenues grew 42% over the prior quarter, reflecting ongoing expansion in the third-line setting.
Streamlined Operations and Cost Reduction
The company reduced its burn rate to approximately $10 million this quarter and achieved a 24% reduction in GAAP operating expenses versus the prior quarter.
Successful Strategic Transactions
Sale of oncology and autoimmune R&D pipeline to Regeneron and the hemophilia A program to Novo Nordisk for $40 million.
Improved Manufacturing Success Rate
Achieved a manufacturing success rate north of 95%, contributing positively to margins.
---
TSVT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSVT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $4.60 | $4.28 | -6.96% |
| Aug 07, 2024 | $4.02 | $4.35 | +8.21% |
| May 08, 2024 | $4.96 | $4.48 | -9.68% |
| Mar 05, 2024 | $5.42 | $5.79 | +6.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does 2seventy bio (TSVT) report earnings?
2seventy bio (TSVT) is schdueled to report earning on Mar 25, 2025, TBA Not Confirmed.
What is 2seventy bio (TSVT) earnings time?
2seventy bio (TSVT) earnings time is at Mar 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSVT EPS forecast?
TSVT EPS forecast for the fiscal quarter 2024 (Q4) is -0.17.
---